Colorectal Cancer

Tweet Chat Recap: Evaluating Treatment Options for Rare Subsets of Colorectal Cancer

April 01, 2020

In honor of Colorectal Cancer Awareness Month, Targeted Oncology was joined by Pashtoon M. Kasi, MD, MBBS, MS, in a tweet chat. The 3 featured cases highlighted a variety of subsets of CRC, including patients with NTRK fusions, BRAF mutations, and HER2 amplifications.

Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors

March 30, 2020

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care

March 30, 2020

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

Sequential Genomic Testing Could Reveal Efficacy, Patterns of Resistance in Metastatic CRC

March 28, 2020

The use of genetic testing by way of tumor tissue analysis combined with liquid biopsy monitoring at different time points throughout the disease progression of colorectal cancer may help optimize treatment selection.

Cetuximab Skin Toxicity Has Predictive and Prognostic Correlation With OS in mCRC

March 25, 2020

The addition of cetuximab to irinotecan, fluorouracil, and folinic acid leucovorin demonstrated superior overall survival compared with the addition of bevacizumab in patients with metastatic colorectal cancer who developed skin toxicity from cetuximab exposure, according to results from the phase II FIRE-3 trial, published in the Annals of Oncology.

Cetuximab Plus Chemotherapy Worsens Survival in Resectable Colorectal Liver Metastases

March 24, 2020

Despite demonstrating improvement in overall survival as treatment of patients with advanced inoperable metastatic colorectal cancer, cetuximab plus chemotherapy led to significantly worse survival for patients with operable colorectal liver metastases in the perioperative setting, according to findings from randomized phase III clinical trial.

South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic

March 23, 2020

In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.

Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations

March 21, 2020

Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.

Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers

March 20, 2020

Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.